Based on evidence that tofacitinib (a JAK1/2/3 inhibitor) rescues STAT hyperphosphorylation in vitro, the individual described by Gruber et al. was treated with tofacitinib, resulting in the resolution of her dermatitis and gastrointestinal symptoms (7). The gene discussed is JAK1; the disease is dermatitis.